Ruifeng Gaocai’s high-end polyester material PBAT-based PETG modification project is set to go into operation soon

Thread Content

On the 24th of the month, Ruifeng High-Performance Materials stated in response to questions from investigators that the company is currently using its existing PBAT production facility with an annual capacity of 60,000 tons. It is investing a total of 10.139 million yuan in upgrades to enable this facility to produce high-end polyester materials such as PETG/PCTG. After the renovation, the project is planned to have an annual production capacity of 30,000 tons, with gradual commissioning expected by mid-2026. PETG/PCTG products have a high degree of synergy with the company’s traditional additive business; both are focused on the plastic products industry, and there are many overlapping customers, enabling the sharing and reuse of customer resources. Polyester PETG is a thermoplastic polyester material that combines strength, toughness, ease of use, and transparency. It is primarily used in industries such as consumer goods packaging, home appliances, sheet and film products, medical devices, and 3D printing. Shandong Ruifeng Polymer Materials Co., Ltd. (formerly Yiyuan Ruifeng Polymer Materials Co., Ltd.) is located in the Economic Development Zone of Yiyuan County, Zibo City, Shandong Province. It was established in 1994 and was restructured into a joint-stock company in 2009; the company went public on the Shenzhen Stock Exchange in 2011. The company is mainly engaged in the research, development, manufacturing, and sales of PVC additives. It is the largest production base in China for acrylate-based impact modifiers and processing aids. Its key products include acrylate-based impact modifiers, acrylate-based processing aids, MBS resin as an impact modifier, and additives for ultra-high molecular weight PVC foam products. In addition, the company is also involved in the field of synthetic biology. Its subsidiary, Ruifeng Biology, is primarily engaged in the development of synthetic biomaterials, and has accumulated certain technical expertise in areas such as polylactic acid, succinic acid, and dextran. Among them, dextran is already being sold on the market normally, and efforts are being made to further expand its market presence; it is used downstream in the production of iron supplements for animals, namely ferrous dextran. In 2026, the company will further increase its production capacity for dextran and expand its sales markets, but this will have no significant impact on performance in the short term. In terms of future plans, the company will expand its product range through both in-house development and partnerships with external technologies, aiming for gradual large-scale implementation.